Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,200 DKK | +0.84% | +2.55% | -9.79% |
Mar. 04 | FDA Extends Review of Zevra's Arimoclomol by Three Months | DJ |
Feb. 21 | Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI). | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
-9.79% | 6.15M | |
+2.73% | 108B | |
+9.59% | 104B | |
+6.58% | 23.66B | |
-12.59% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.29% | 16.19B | |
+4.68% | 13.72B | |
+34.25% | 12.22B |
- Stock
- Equities
- Stock Orphazyme A/S - Nasdaq Copenhagen
- News Orphazyme A/S
- Orphazyme A/S : Says European Review of Arimoclomol Underway; Raises 2021 Cash Position Outlook